Safe sex revolution means new options: soon condoms won’t be your only choice
HIV advocates and researchers admit that many people do not use condoms. Now there are revolutionary new ways of preventing HIV infection including taking a pill day.
Elton John AIDS Foundation supports Health4Men
A new $7 million grant for the Anova Health Institute’s Health4Men project to address HIV in South Africa’s gay, bisexual and MSM (men who have sex with men) community has been announced in both Washington and Johannesburg. This significant international funding boost to expand MSM-targeted HIV-related services in South Africa is the result of a new partnership between the Elton John AIDS Foundation and the US President’s Emergency Plan for AIDS Relief (PEPFAR).
FDA Approves Harvoni, Gilead’s Sofosbuvir/Ledipasvir Combo Pill for Hepatitis C
On October 10, the U.S. Food and Drug Administration (FDA) approved a new once-daily combination pill for the treatment of genotype 1 chronic hepatitis C containing Gilead Sciences’ HCV nucleotide polymerase inhibitor sofosbuvir (Sovaldi) plus ledipasvir, the first approved HCV NS5A inhibitor.
ED Drugs Associated with Sexual Risk Behaviors and STIs in HIV+ Men
Use of prescription erectile dysfunction (ED) medication was significantly associated with sexual risk behavior in HIV-positive men, according to data presented at IDWeek 2014 by Greer Burkholder, MD, of the Infectious Diseases Department, University of Alabama at Birmingham.
TECHNICAL BRIEFS ON HIV & YOUNG KEY POPULATIONS
To help address the HIV epidemic among young members of key populations, the United Nations Interagency Working Group on Key Populations has produced a series of technical briefs focused on the needs and realities of young men who have sex with men, young people who sell sex, young people who use drugs, and young transgender people.
Half of HIV Positive Gay and Bisexual Men Are Untreated
Two new studies indicate differences in treatment among racial groups.
Long acting HIV drugs to be developed
HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of ‘pill fatigue’.
Gene Therapy May Hold Key to HIV Cure, If Government Allows It
Using patients’ genetic material to help attack their particular version of HIV.
New Single-Tablet Regimen: FDA Approves Triumeq
ViiV Healthcare’s single-tablet regimen Triumeq won Food and Drug Administration approval on August 22, 2014. Triumeq is the first FDA-approved single-tablet regimen (STR) that does not contain tenofovir (Viread), a widely used antiretroviral drug linked with bone and kidney problems in some susceptible HIV-positive individuals.
STUDY: HIV Drug Resistance Linked to Long Term Use of Certain Antiretrovirals
A meta-analysis of HIV patients in China shows strong relationship between didanosine-based treatments and increase in drug resistance.